期刊
TRENDS IN MOLECULAR MEDICINE
卷 26, 期 8, 页码 713-715出版社
CELL PRESS
DOI: 10.1016/j.molmed.2020.06.001
关键词
-
The clinical application of CRISPR-Cas9 gene editing has been eagerly awaited since the first description of the technique in 2013. Lu and colleagues now describe the treatment of 12 patients with nonsmallcell lung cancer (NSCLC) with PD-1 gene-edited bulk autologous T cells, with results supporting both the feasibility and safety of gene editing in cell therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据